Setting higher standards for migraine prevention: A position statement of the International Headache Society

The IHS advocates the higher goals based on the positive impact of new treatment advancements such as calcitonin gene-related peptide (CGRP) pathway inhibitors introduced in the past decade, as well as other agents showing strong results in clinical trials.

In Australia, around 4.9 million people live with migraine, with 86% of them being of working age. Women represent 72% of those affected, with migraine impacting fertility and family planning, and causing stigma that can impact their career growth and mental health. The total economic cost of migraine in Australia is estimated at $35.7 billion per year.

Read the full report here:

https://www.georgeinstitute.org/news/the-george-institute-welcomes-new-international-push-to-raise-the-bar-in-migraine

Read the paper here:

https://journals.sagepub.com/doi/10.1177/03331024251320608